How many is good enough? An analysis of serological follow-up after vaccination against SARS-CoV-2
, , , , , y | 28 dic 2023
Acerca de este artículo
Article Category: Original Study
Publicado en línea: 28 dic 2023
Páginas: 143 - 153
Recibido: 14 oct 2022
Aceptado: 21 mar 2023
DOI: https://doi.org/10.2478/ahem-2023-0020
Palabras clave
© 2023 Monika Stępień et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Minimal (min), maximal (max), median (Me), IQR (Interquartile range), SD (standard deviation) and mean results [IU/ml] on following stages of the study. A (COVID-19 convalescents with increase of antibody level after 2nd dose) – 27 patients, B (naïve patients) - 30, C (COVID-19 convalescent, who had lower antibody level after 2nd dose compared to the results after 1st dose). - 30; 87 participants in total. P-value was find using Kruskal-Wallis test
| group | Mean [IU/mL] | SD [IU/mL] | Min-max [IU/mL] | Me [IQR] [IU/mL] | P | |
|---|---|---|---|---|---|---|
| D0 | A | 162.4 | 182.8 | 0.0–896.0 | 92.8 [44.2–227.7] | 0.000 |
| C | 222.0 | 289.5 | 0.0–1344.0 | 128.1 [83.2–268.8] | ||
| B | 0.000 | 0.000 | 0.0–0.0 | 0.000 [0–0] | ||
| total | 127.0 | 218.0 | 0.0–1344.0 | 57.6 [0.0–144.5] | ||
| D1 | A | 5959.5 | 2415.7 | 1830.4–11392.0 | 5587.2 [4480.0–7680.0] | 0.000 |
| C | 7638.5 | 5390.0 | 1968.0–21800.0 | 5472.0 [4000.0–8256.0] | ||
| B | 856.0 | 875.1 | 185.6–3088.0 | 536.0 [320.0–889.6] | ||
| total | 4778.6 | 4525.2 | 185.6–21800.0 | 4000.0 [777.9–6075.0] | ||
| D2 | A | 7664.4 | 2616.5 | 3360.0–14360.0 | 7520.0 [4992.0–9280.0] | 0.000 |
| C | 5547.2 | 3845.9 | 1129.0–19840.0 | 4608.0 [3120.0–7456.0] | ||
| B | 4451.9 | 1569.1 | 1664.0–7680.0 | 4032.0 [3360.0–5440.0] | ||
| total | 5826.6 | 3103.9 | 1129.0–19840.0 | 4832.0 [3456.0–7536.0] | ||
| D3 | A | 2417.1 | 1480.2 | 344.0–7316.0 | 2336.0 [1453.0–3096.0] | 0.000 |
| C | 2146.4 | 2453.0 | 236.0–12099.0 | 1462.5 [819.0–2177.0] | ||
| B | 965.4 | 485.8 | 340.0–2650.0 | 819.0 [609.0–1216.0] | ||
| total | 1823.2 | 1781.8 | 236.0–12099.0 | 1301.0 [806.0–2336.0] |
Correlation between baseline (D0) antibody levels and further sampling (D1 - after 1st dose - up to 7 days before the second dose, D2 – 1 month after vaccination, D3 – 6 months after vaccination)
| Antibody levels | Spearman rank correlation | ||
|---|---|---|---|
| N | R Spearman | p | |
| D0 & D1 | 87 | 0.73 | 0.000 |
| D0 & D2 | 87 | 0.34 | 0.001 |
| D0 & D3 | 87 | 0.45 | 0.000 |
Delta (difference) between antibody levels 1 month after vaccination (D2) and 6 months after vaccination (D3); minimal (min), maximal (max), median (Me), IQR, SD (standard deviation), N – number of subjects, total – summary number of participants. P-value was find using Kruskal-Wallis test
| group | Mean [IU/mL] | N | SD [IU/mL] | Min-max [IU/mL] | Me [IQR] [IU/mL] | p |
|---|---|---|---|---|---|---|
| A | 5247.2 | 27 | 2566.4 | 1383.0–13459.0 | 5389.0 [3354.0–7134.0] | 0.003 |
| C | 3400.8 | 30 | 1811.0 | 756.0–7741.0 | 3158.5 [2024.0–5012.0] | |
| B | 3486.5 | 30 | 1461.3 | 614.0–6331.0 | 3105.0 [2654.0–4538.0] | |
| total | 4003.4 | 87 | 2126.7 | 614.0–13459.0 | 3505.0 [2496.0–5535.0] |